Saturday, 16 April 2011

GSK buy-in impossible without transition managers

Raquel Pichardo-Allison reports in Global Pensions (15 April 2011) that GlaxoSmithKline’s £900m ($1.5bn) buy-in deal last year would not have been possible without transition managers.

GSK entered into a buy-in deal with Prudential in November of last year. Martin Mannion from GSK said, "I don't think the deal was physically possible without a transition manager because you had potential contracts you were entering into, you were attempting to hedge, you were attempting to buy into their wish-list ahead of time... So I think that's in the category of ‘don't even go there without a TM'."

The transition event lasted nine months.

Read the full article here.

Sovereign Investor:  Do you use transition managers?  Do you use a single firm or have access to a panel?

No comments:

Post a Comment